Academic Journal
Regenerating smell in neurodegenerative disease -translating theory into therapy.
| Τίτλος: | Regenerating smell in neurodegenerative disease -translating theory into therapy. |
|---|---|
| Συγγραφείς: | Di Stadio A; Department of Life and Health Science, Link University of Rome, Rome, Italy. ariannadistadio@hotmail.com.; IRCSS Santa Lucia Foundation, Rome, Italy. ariannadistadio@hotmail.com., Brenner MJ; Department of Otolaryngology - Head and Neck Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA., De Luca P; IRCSS Santa Lucia Foundation, Rome, Italy.; Santa Rosa Hospital, Viterbo, Italy., D'Ascanio L; Department of Otolaryngology, Ospedali Riuniti Marche Nord, Fano, Italy., Patel ZM; Department of Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, CA, USA. |
| Πηγή: | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery [Eur Arch Otorhinolaryngol] 2026 Sep; Vol. 283 (9), pp. 6103-6108. Date of Electronic Publication: 2026 May 21. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer International Country of Publication: Germany NLM ID: 9002937 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1434-4726 (Electronic) Linking ISSN: 09374477 NLM ISO Abbreviation: Eur Arch Otorhinolaryngol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Heidelberg : Springer International, c1990- |
| Ιατρικοί όροι (MeSH): | Olfaction Disorders*/therapy , Olfaction Disorders*/etiology , Olfaction Disorders*/physiopathology , Neurodegenerative Diseases*/complications , Neurodegenerative Diseases*/therapy , Neurodegenerative Diseases*/physiopathology , Smell*/physiology , Platelet-Rich Plasma*, COVID-19/complications ; Humans ; Olfactory Training ; SARS-CoV-2 |
| Περίληψη: | Purpose: Quantitative and qualitative olfactory dysfunction are one of the earliest and most prevalent symptoms across neurodegenerative diseases, notably Parkinson's and Alzheimer's disease. These pathologies may spread bidirectionally between the peripheral olfactory system and central brain regions, supporting a model in which the olfactory system represents both an early marker and a conduit for disease propagation. This short communication aims to investigate the potential of Platelet Rich Plasma (PRP) to treat smell alteration in the neurodegenerative diseases. Method: We conducted a review of the literature to extract articles that discussed PRP use in the context of olfactory disorders. Results: 12 studies were identified; 7 studies on COVID-19, 2 on unspecific smell loss, 1 on traumatic anosmia, 1 on nasal polyposis and 1 illustrated the use of PRP in long-term persistent anosmia (> 25 years). Conclusion: Post COVID-19 olfactory impairment has provided insights into mechanisms of smell loss and therapeutic strategies. While olfactory training remains the best studied intervention, its benefits are modest, inconsistent, and often limited in cases with central nervous system involvement. PRP has emerged as a promising candidate due to its growth factors and immunomodulatory properties. Preclinical studies demonstrate that intranasal PRP can enhance neurogenesis, reduce neuroinflammation, and improve olfactory and cognitive outcomes in animal models of Parkinson's and Alzheimer's disease. Early clinical observations also suggest potential benefit in longstanding anosmia of diverse etiologies. Future research should define optimal delivery routes, dosing, and long-term efficacy, with well-designed clinical trials needed to translate these experimental findings into therapeutic applications. (© 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| Competing Interests: | Declarations. Disclosures: Zara M. Patel is a cofounder and holds equity in Olfera Therapeutic. |
| References: | Cells. 2022 Aug 17;11(16):. (PMID: 36010630) Mov Disord Clin Pract. 2023 Jun 12;10(7):1146-1149. (PMID: 37476306) Int Forum Allergy Rhinol. 2023 Jun;13(6):989-997. (PMID: 36507615) Int Forum Allergy Rhinol. 2016 Mar;6(3):299-307. (PMID: 26624966) Nat Rev Immunol. 2022 Nov;22(11):657-673. (PMID: 35246670) Nat Commun. 2020 Jan 17;11(1):354. (PMID: 31953399) J Control Release. 2015 Apr 10;203:170-80. (PMID: 25702964) J Clin Med. 2025 Sep 18;14(18):. (PMID: 41010778) J Clin Med. 2024 Jan 29;13(3):. (PMID: 38337476) Lancet Neurol. 2017 Jun;16(6):478-488. (PMID: 28504111) Front Neurol. 2023 Jul 31;14:1208213. (PMID: 37583957) Cell Host Microbe. 2024 Dec 11;32(12):2112-2130.e10. (PMID: 39615487) Cerebrospinal Fluid Res. 2004 Dec 10;1(1):2. (PMID: 15679948) Int J Mol Sci. 2024 Nov 10;25(22):. (PMID: 39596147) Otolaryngol Head Neck Surg. 2021 Feb;164(2):244-254. (PMID: 32660334) JAMA Otolaryngol Head Neck Surg. 2025 Apr 1;151(4):412-413. (PMID: 39913151) Rhinology. 2025 Jun 1;63(3):325-333. (PMID: 40202093) Neurobiol Aging. 2003 Mar-Apr;24(2):197-211. (PMID: 12498954) Nat Commun. 2022 Apr 1;13(1):1745. (PMID: 35365631) Neuro Endocrinol Lett. 2023 Sep 29;44(6):418-425. (PMID: 37776559) J Clin Med. 2022 Jun 08;11(12):. (PMID: 35743346) ORL J Otorhinolaryngol Relat Spec. 2021;83(6):387-394. (PMID: 34107478) Front Physiol. 2022 Jan 04;12:769948. (PMID: 35058794) |
| Contributed Indexing: | Keywords: Alzheimer’s disease; Anosmia; Chronic olfactory dysfunction; Neurodegeneration; Olfaction; PRP; Parkinson’s disease; Platelet-rich plasma; Smell; Smell loss |
| Entry Date(s): | Date Created: 20260521 Date Completed: 20260925 Latest Revision: 20261008 |
| Update Code: | 20261008 |
| DOI: | 10.1007/s00405-026-10279-9 |
| PMID: | 42165881 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1434-4726 |
|---|---|
| DOI: | 10.1007/s00405-026-10279-9 |